Making Complex Science Simple

From the company’s inception, ProteoGenix has made a significant investment into advancing the science of pregnancy-related complications. Through its unique approach to the science of discovery, and leveraging strong relationships with marquee healthcare institutions and key thought leaders, ProteoGenix has established a scientific and clinical framework to achieve success in discovery, development and commercialization.

Utilizing core scientific strengths, ProteoGenix has taken a logical, evidence-based approach to developing tests that are clinically practical and provide medically useful information in a way that offers significant advantages over currently available options.

• Molecular Diagnostics - highly accurate nucleic acid-based technologies that detect and identify pathogenic microorganisms. Can be used as clinical diagnostic tools and also in the ProteoGenix discovery process to select proteomic biomarkers that specifically correlate with targeted infectious/pathophysiological diseases

• Genomics - serves as the template upon which the science of proteomics was based

• Proteomics - ProteoGenix’ core science that enables identification of key, newly identified biomarkers

• Bioinformatics - statistical analysis of complex data sets to discover new protein biomarkers and biomarker relationships that can be used to develop proprietary algorithms that link biomarker combinations and concentrations to the diagnosis of maternal, fetal and neonatal disorders

ProteoGenix has utilized high-throughput protein analysis techniques to identify protein biomarkers for pregnancy-related complications. Utilizing primate models and human samples, the company has identified over 800 individual proteins relevant to pregnancy from analyses of amniotic fluid, cervical-vaginal fluid (CVF), umbilical cord blood and maternal serum samples. ProteoGenix uses these identified proteins in combination with nucleic acid-based molecular technologies as the basis for correlating specific biomarkers with common maternal, fetal and neonatal disorders.

ProteoGenix has demonstrated the use of multiple biomarkers in diagnostic tests, rendering it superior to both conventional single-marker, and proteomics-based pattern-recognition technologies. The advantages of rapid, easy-to-interpret tests using CVF or other fluids, in combination with nucleic acid-based molecular diagnostic tests specifically optimized for use with the key maternal/fetal/neonatal biological fluids, create compelling opportunities for future diagnostic products and laboratory services.